Results 71 to 80 of about 9,430 (168)

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation

Health Technology Assessment, 2016
Objectives: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with increasing disability, reduced quality of life and substantial costs (as a result of both intervention acquisition and hospitalisation).
Matt Stevenson, Rachel Archer, Jon Tosh, Emma Simpson, Emma Everson-Hock, John Stevens, Monica Hernandez-Alava, Suzy Paisley, Kath Dickinson, David Scott, Adam Young, Allan Wailoo   +11 more
doaj   +1 more source

Specialty‐Based Disparities in Biologic Use and Retention in Psoriatic Arthritis: A Nationwide Korean Claims Analysis

International Journal of Rheumatic Diseases, Volume 29, Issue 7, July 2026.
ABSTRACT Aim Biologic agents play a pivotal role in controlling both articular and cutaneous manifestations of psoriatic arthritis (PsA). Although international guidelines emphasize the appropriate use of biologics, Korea lacks standardized treatment protocols tailored for PsA across specialties.
Bon San Koo, Ye‐Jee Kim, Yeo‐Jin Lee, Yong‐Gil Kim, Tae‐Hwan Kim   +4 more
wiley   +1 more source

Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis

Drug, Healthcare and Patient Safety, 2016
Daniela Pugliese, Carla Felice, Rosario Landi, Alfredo Papa, Luisa Guidi, Alessandro Armuzzi Inflammatory Bowel Disease Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy Abstract: Significant advances in the management of patients ...
Pugliese D, Felice C, Landi R, Papa A, Guidi L, Armuzzi A   +5 more
doaj  

Glomerulonephritis as a variant of extra-intestinal manifestation of ulcerative colitis

Alʹmanah Kliničeskoj Mediciny, 2018
Studies of inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn's disease, is highly relevant due to their growing incidence and prevalence, and a wide range of extraintestinal manifestations.
O. Yu. Barysheva, A. S. Atamanova, A. A. Samusenko, V. A. Strategopulo, E. A. Lyutaya, N. N. Vezikova, K. E. Egorova   +6 more
doaj   +1 more source

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 2, Page 235-242, July 2026.
In a real‐world cohort of patients with highly refractory perianal Crohn's disease, upadacitinib induced clinical remission at 12 months in 26% of patients with fistulizing disease and 25% of those with isolated anal ulcerations. ABSTRACT Introduction Upadacitinib (UPA) is effective for treating luminal Crohn's disease (CD), but data on perianal CD ...
Nicolas Richard, Philippe Seksik, Romain Altwegg, Maria Nachury, David Laharie, Stéphane Nancey, Benoît Coffin, Anne‐Laure Pelletier, Mathieu Uzzan, Aurélien Amiot, Morgane Amil, Lucine Vuitton, Mathurin Fumery, Anne Bozon   +13 more
wiley   +1 more source

Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug‐Induced Liver Injury Network Experience

Liver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background We aimed to investigate and characterise DILI due to approved therapies for inflammatory bowel disease (IBD). Methods Using the Drug‐Induced Liver Injury Network (DILIN) prospective study, we evaluated definite, highly likely, or probable DILI attributed to IBD therapies, including use for non‐IBD indications (but excluding ...
Harish Gopalakrishna, Jiezhun Gu, Yi‐Ju Li, Huiman Barnhart, Dina Halegoua‐DeMarzio, Herbert L. Bonkovsky, A. Sidney Barritt, Jean P. Molleston, Naga P. Chalasani, Marwan Ghabril   +9 more
wiley   +1 more source

Choice of therapeutic tactics after failure of the first tumor necrosis factor-α inhibitor

Современная ревматология, 2017
The paper discusses whether the effect of different biological agents (BAs) can be achieved in patients with active rheumatoid arthritis (RA) when they inadequately respond to therapy with tumor necrosis factor-α (TNF-α) inhibitors.
N. V. Chichasova
doaj   +1 more source

AA Amyloidosis Resulting From Unintended Discontinuation of Rheumatoid Arthritis Therapy due to Cognitive Impairment

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Amyloid A (AA) amyloidosis is a serious complication of chronic inflammatory diseases, including rheumatoid arthritis (RA). A 78‐year‐old woman with advanced dementia developed progressive renal dysfunction following prolonged, unintentional RA treatment discontinuation.
Kenji Ishiguro, Shunta Kaneko
wiley   +1 more source

Safety and clinical efficacy of golimumab in the treatment of arthritides

Drug, Healthcare and Patient Safety, 2010
Ismail Simsek, Yusuf YaziciNew York University School of Medicine, NYU Hospital for Joint Diseases, New York, USAAbstract: Golimumab is a human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody that was recently approved for the treatment of ...
Ismail Simsek, Yusuf Yazici
doaj  

A Systematic Review of Literature: TNF‐α Blockers and JAK Inhibitors for the Treatment of Stevens‐Johnson Syndrome, Toxic Epidermal Necrolysis, and Severe Forms of Erythema Multiforme

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aims Stevens‐Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme major (EM major) are severe dermatologic conditions characterized by varying degrees of skin detachment and involvement of mucosal membranes, often triggered by drug reactions or infections.
Sadaf Salehi, Pooneh Torabi, Mahsa Abbaspour, Nima Hajizadeh, Sara Sadeghi, Alireza Jafarzadeh, Azadeh Goodarzi   +6 more
wiley   +1 more source